Search results for "VASCULITIS"

showing 10 items of 118 documents

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.

2015

Importance BRAF inhibitors have been licensed for the therapy of BRAF-mutated melanoma. Recently, inflammatory skin lesions clinically resembling erythema nodosum have been reported as therapy side-effects that may lead to treatment discontinuation. Objective To identify and characterize cases with BRAF inhibitor-associated erythema nodosum-like inflammatory skin lesions and development of an algorithm for their management. Design and Setting Retrospective chart review of melanoma patients treated with BRAF inhibitors in 14 departments of Dermatology in Germany and Austria and PubMed search for cases in the literature. Results Sixteen patients were identified who developed erythema nodosum-…

AdultMaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyIndolesErythemaBiopsyMedizinDermatology030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineErythema NodosumOximesmedicineHumansskin and connective tissue diseasesVemurafenibneoplasmsAgedRetrospective StudiesSkinTrametinibErythema nodosumSulfonamidesintegumentary systembusiness.industryMelanomaImidazolesDabrafenibMiddle Agedmedicine.diseaseDermatology3. Good healthInfectious DiseasesVemurafenib030220 oncology & carcinogenesisFemalemedicine.symptombusinessPanniculitisVasculitismedicine.drugJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded …

2006

Objective: To evaluate the feasibility of haematopoietic stem cell transplantation (HSCT) in vasculitis. Methods: This is a retrospective analysis of patients who had received HSCT for vasculitic diseases and have been reported to the European League Against Rheumatism autoimmune disease or European Bone Marrow Transplantation ProMISe databases. Information about the disease and outcome was obtained by a questionnaire sent to the referring centres. Response of the disease to HSCT was defined as partial or complete responses according to the ability to reduce immunosuppression after HSCT. In addition, the Medline database was searched for reports on HSCT in patients with vasculitis. Results:…

AdultMaleReoperationVasculitisDatabases Factualmedicine.medical_treatmentMEDLINEImmunologyBehcet's diseasecomputer.software_genreTransplantation AutologousGeneral Biochemistry Genetics and Molecular BiologyRheumatologyimmune system diseasesRecurrencehemic and lymphatic diseasesmedicineImmunology and AllergyHumansTransplantation HomologousRetrospective StudiesImmunosuppression TherapyDatabasePolyarteritis nodosabusiness.industryBehcet SyndromeHematopoietic Stem Cell TransplantationRetrospective cohort studyImmunosuppressionmedicine.diseaseConnective tissue diseaseTransplantationExtended ReportEuropesurgical procedures operativeTreatment OutcomeFemalebusinessVasculitiscomputerCartilage DiseasesRheumatism
researchProduct

Diseases of the vertebral arteries.

1990

Case reports and postmortem neuropathological findings of a wide spectrum of diseases affecting the vertebral arteries, in particular vasculitis, traumatic lesions, degenerative changes and congenital abnormalities, are discussed.

AdultMaleVasculitisPathologymedicine.medical_specialtySystemic diseaseVertebral arteryAneurysmmedicine.arteryMedicineHumansChiropractic manipulationVertebral ArteryAgedAged 80 and overbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseGiant cell arteritisSurgeryFemalesense organsNeurology (clinical)NeurosurgerybusinessVasculitisNeurosurgical review
researchProduct

Serum thrombomodulin—a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters t…

1999

SUMMARYTo date no specific serological parameter is available to assess disease activity in SLE. Soluble serum thrombomodulin is a new marker of endothelial cell injury and vasculitis. The objective of this study was to compare in vivo soluble thrombomodulin as marker of disease activity in SLE with established and recent serological parameters. One hundred and twenty-four sera of 30 patients with proven SLE with different disease activities were tested for serum levels of thrombomodulin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, vascular cell adhesion molecule-1 (VCAM-1), IL-2R, IL-6, IL-10, dsDNA by ELISA and dsDNA additionally by radioimmunoassay (RIA). C-reactive protein (…

AdultMaleVasculitisSystemic diseaseAdolescentThrombomodulinImmunologyVascular Cell Adhesion Molecule-1ThrombomodulinSerologyRheumatic DiseaseImmunopathologymedicineHumansLupus Erythematosus SystemicImmunology and Allergyskin and connective tissue diseasesAgedAutoimmune diseaseLupus erythematosusmedicine.diagnostic_testbusiness.industryMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseConnective tissue diseaseSolubilityCase-Control StudiesErythrocyte sedimentation rateImmunologycardiovascular systemFemaleE-SelectinbusinessBiomarkersClinical and Experimental Immunology
researchProduct

Continuous therapy with transdermal nitroglycerin does not affect biomarkers of vascular inflammation and injury in healthy volunteers.

2009

Continuous exposure to nitroglycerin (GTN) results in development of tolerance and is associated with increased free radical production and abnormal endothelial function. Elevated plasma biomarkers of inflammation have been shown to be associated with endothelial dysfunction in most cardiovascular conditions. It remains unclear whether exposure to GTN is also associated with increased biomarkers of endothelial and vascular injury or vascular inflammation. In an investigator-blind study, a total of 28 healthy volunteers were randomized to continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days) or no therapy. Venous blood was collected on day 0 and day 7. Plasma levels of markers such as …

AdultMaleVasculitisTime FactorsEndotheliumAdolescentPhysiologyVasodilator AgentsInflammationPharmacologyAdministration CutaneousArginineLesionNitroglycerinYoung AdultPhysiology (medical)MedicineHumansEndothelial dysfunctionTransdermalPharmacologyDose-Response Relationship Drugbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaGeneral MedicineVenous bloodmedicine.diseaseLipoproteins LDLDose–response relationshipP-Selectinmedicine.anatomical_structureAnesthesiacardiovascular systemTumor necrosis factor alphaEndothelium Vascularmedicine.symptombusinessCell Adhesion MoleculesBiomarkerscirculatory and respiratory physiologyCanadian journal of physiology and pharmacology
researchProduct

Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: Impact on global disability and health-related quality of life

2016

IF 2.724 (2014); International audience; OBJECTIVES: To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy. METHODS: In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed. RESULTS: Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demons…

AdultMale[ SDV ] Life Sciences [q-bio][SDV]Life Sciences [q-bio]Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMiddle Aged[SDV] Life Sciences [q-bio]AzathioprineQuality of LifeHumansDisabled PersonsFemaleRituximabAged
researchProduct

Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.

2020

Abstract Purpose The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) patients’ cohort. Materials and methods Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on the treatment modalities. Results There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic granulomatosis with polyangiitis (EGPA; 16.3%). The mean ag…

AdultMalemedicine.medical_specialtyCyclophosphamideDrug-Related Side Effects and Adverse ReactionsAzathioprineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicineAzathioprinemedicineHumansTreatment complications030212 general & internal medicineRegistriesAdverse effectCyclophosphamideGlucocorticoidsANCA associated vasculitisRetrospective Studiesbusiness.industryVasculitis registryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival RateMethotrexate030220 oncology & carcinogenesisCohortRituximabDrug Therapy CombinationFemalePolandMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessRituximabVasculitis treatmentImmunosuppressive Agentsmedicine.drugFollow-Up StudiesAdvances in medical sciences
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct

Effects of Estrogen on Vascular Inflammation

2012

Objective— Our study aims to determine the role of time of menopause on vascular inflammation biomarkers and how it affects their modulation by estrogen and raloxifene in postmenopausal women. Methods and Results— Uterine arteries from 68 postmenopausal women were divided into 3 segments and cultured for 24 hours in tissue culture media containing 17β-estradiol (100 nmol/L), raloxifene (100 nmol/L), or vehicle. Assessment of arterial concentration of 13 inflammatory biomarkers was performed by multiplex immunobead-based assay. Aging per se has a positive correlation with the generation of several proinflammatory markers. Although short-term estradiol exposure correlates with lower expressi…

AdultVasculitisAgingmedicine.medical_specialtyTime Factorsmedicine.drug_classEstrogen receptorProinflammatory cytokinechemistry.chemical_compoundInternal medicinemedicineEstrogen Receptor betaHumansRaloxifeneEstrogen receptor betaAgedInterleukin-6business.industryEstrogen Receptor alphaEstrogensMiddle Agedmedicine.diseaseMenopauseVascular endothelial growth factorHormones esteroidesEndocrinologychemistryEstrogenRaloxifene HydrochlorideFemaleMenopauseCardiology and Cardiovascular MedicinebusinessEstrogen receptor alphahormones hormone substitutes and hormone antagonistsBiomarkersMenopausamedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Endovascular Management, with the Use of Solitaire Stent as the First-Line Treatment for Cerebral Vasculitis: A Case Report

2019

Cerebral vasculitis that comprises a group of noninfectious inflammatory vasculitides, can produce a variety of neurologic events, including also life-threatening ones. In this paper we describe the case report of a 37-year-old female patient with cerebral vasculitis manifesting as ischemic stroke of the left cerebral hemisphere. Her clinical status deteriorated, despite immunosuppression. CT angiography demonstrated several occlusions of intracranial arteries. We describe details of endovascular revascularization of intracranial arteries in this patient, with focus at the use of the Solitaire stent, which seems to be particularly useful in such challenging cases. After endovascular repair …

AngioplastyCerebral vasculitisStentsJournal of Neuroscience and Neurosurgery
researchProduct